JP2012121878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012121878A5 JP2012121878A5 JP2011207654A JP2011207654A JP2012121878A5 JP 2012121878 A5 JP2012121878 A5 JP 2012121878A5 JP 2011207654 A JP2011207654 A JP 2011207654A JP 2011207654 A JP2011207654 A JP 2011207654A JP 2012121878 A5 JP2012121878 A5 JP 2012121878A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- antigen
- binding fragment
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46921103P | 2003-05-08 | 2003-05-08 | |
| US60/469,211 | 2003-05-08 | ||
| US55762104P | 2004-03-29 | 2004-03-29 | |
| US55762204P | 2004-03-29 | 2004-03-29 | |
| US55762004P | 2004-03-29 | 2004-03-29 | |
| US60/557,622 | 2004-03-29 | ||
| US60/557,621 | 2004-03-29 | ||
| US60/557,620 | 2004-06-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532992A Division JP4887152B2 (ja) | 2003-05-08 | 2004-05-10 | 抗ｃｓ１抗体の治療的使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014030549A Division JP6042834B2 (ja) | 2003-05-08 | 2014-02-20 | 抗ｃｓ１抗体の治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012121878A JP2012121878A (ja) | 2012-06-28 |
| JP2012121878A5 true JP2012121878A5 (enExample) | 2012-11-08 |
| JP5976288B2 JP5976288B2 (ja) | 2016-08-23 |
Family
ID=33459144
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532992A Expired - Lifetime JP4887152B2 (ja) | 2003-05-08 | 2004-05-10 | 抗ｃｓ１抗体の治療的使用 |
| JP2011207654A Expired - Lifetime JP5976288B2 (ja) | 2003-05-08 | 2011-09-22 | 抗ｃｓ１抗体の治療的使用 |
| JP2014030549A Expired - Lifetime JP6042834B2 (ja) | 2003-05-08 | 2014-02-20 | 抗ｃｓ１抗体の治療的使用 |
| JP2016142300A Pending JP2017019795A (ja) | 2003-05-08 | 2016-07-20 | 抗ｃｓ１抗体の治療的使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532992A Expired - Lifetime JP4887152B2 (ja) | 2003-05-08 | 2004-05-10 | 抗ｃｓ１抗体の治療的使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014030549A Expired - Lifetime JP6042834B2 (ja) | 2003-05-08 | 2014-02-20 | 抗ｃｓ１抗体の治療的使用 |
| JP2016142300A Pending JP2017019795A (ja) | 2003-05-08 | 2016-07-20 | 抗ｃｓ１抗体の治療的使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US20050025763A1 (enExample) |
| EP (4) | EP1624892B1 (enExample) |
| JP (4) | JP4887152B2 (enExample) |
| KR (1) | KR101268707B1 (enExample) |
| CN (1) | CN1805755B (enExample) |
| AT (1) | ATE506076T1 (enExample) |
| AU (2) | AU2004238363B2 (enExample) |
| BE (1) | BE2016C056I2 (enExample) |
| BR (1) | BRPI0410129B8 (enExample) |
| CA (1) | CA2523001C (enExample) |
| CY (4) | CY1111958T1 (enExample) |
| DE (1) | DE602004032328D1 (enExample) |
| DK (3) | DK2853272T3 (enExample) |
| ES (2) | ES2516840T3 (enExample) |
| FR (1) | FR16C1012I2 (enExample) |
| HK (1) | HK1208815A1 (enExample) |
| HU (2) | HUE034908T2 (enExample) |
| LT (1) | LT2853272T (enExample) |
| LU (1) | LU93274I2 (enExample) |
| MX (1) | MXPA05012011A (enExample) |
| NL (1) | NL300838I2 (enExample) |
| PL (3) | PL2853272T3 (enExample) |
| PT (3) | PT2371391E (enExample) |
| SI (3) | SI2371391T1 (enExample) |
| WO (1) | WO2004100898A2 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2008019379A2 (en) * | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| PL2068930T3 (pl) * | 2006-08-07 | 2013-02-28 | Abbvie Biotherapeutics Inc | Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego |
| PT2641601T (pt) | 2006-08-07 | 2016-10-14 | Dana Farber Cancer Inst Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib |
| JP2011523560A (ja) * | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク． | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| WO2010051391A1 (en) * | 2008-10-31 | 2010-05-06 | Facet Biotech Corporation | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| EP2382321A4 (en) * | 2009-01-08 | 2012-12-19 | Bio Rad Laboratories | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF NUCLEIC ACID AMPLIFICATION REACTIONS |
| WO2011060076A1 (en) * | 2009-11-10 | 2011-05-19 | Amgen Inc. | Anti-c-mpl antibodies |
| KR20130028055A (ko) * | 2010-01-28 | 2013-03-18 | 글락소 그룹 리미티드 | Ｃｄ １２７ 결합 단백질 |
| AR080301A1 (es) | 2010-02-24 | 2012-03-28 | Immunogen Inc | Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos |
| PL2694106T3 (pl) | 2011-04-01 | 2018-06-29 | Immunogen, Inc. | Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1 |
| KR20150046316A (ko) | 2012-08-31 | 2015-04-29 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트 |
| CA2888803A1 (en) | 2012-11-05 | 2014-05-08 | Jooeun Bae | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| JP2016515524A (ja) * | 2013-03-15 | 2016-05-30 | アッヴィ バイオテクノロジー リミテッド | 抗ｃｄ２５抗体およびそれらの使用 |
| BR112015022119A2 (pt) * | 2013-03-15 | 2017-08-29 | Abbvie Biotherapeutics Inc | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento |
| EP2992020B1 (en) * | 2013-05-03 | 2020-01-15 | Ohio State Innovation Foundation | Cs1-specific chimeric antigen receptor engineered immune effector cells |
| WO2015013508A2 (en) * | 2013-07-24 | 2015-01-29 | The General Hospital Corporation | Methods for diagnosing and treating immune disease |
| PT3038650T (pt) | 2013-08-30 | 2021-08-25 | Immunogen Inc | Anticorpos e ensaios para a deteção do recetor de folato 1 |
| US9482289B2 (en) | 2013-10-14 | 2016-11-01 | Club Car, Llc | Self-preloading shift lever |
| ES2707057T3 (es) | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| EP3066127A1 (en) | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2015166056A1 (en) * | 2014-05-02 | 2015-11-05 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| PT3157561T (pt) * | 2014-06-17 | 2020-03-25 | Univ California | Anticorpos contra alfa-v beta-8 melhorados |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US10752902B2 (en) * | 2014-09-23 | 2020-08-25 | Board Of Trustees Of Michigan State University | Compositions comprising fusion proteins useful for modulating an immune response |
| WO2016070089A2 (en) | 2014-10-31 | 2016-05-06 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| US20170355768A1 (en) | 2014-12-04 | 2017-12-14 | Bristol-Myers Squibb Company | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
| DE102015102183B4 (de) * | 2015-02-16 | 2018-03-01 | Robert Bosch Automotive Steering Gmbh | Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug |
| EP3258967A4 (en) | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| WO2016168766A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized chimeric receptor t cell switches and uses thereof |
| SI3313528T1 (sl) | 2015-06-29 | 2021-11-30 | Bristol-Myers Squibb Company | Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| JP6880006B2 (ja) | 2015-09-17 | 2021-06-02 | イミュノジェン， インコーポレイテッド | 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ |
| KR20250099459A (ko) * | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| JP7222550B2 (ja) | 2017-03-13 | 2023-02-15 | イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー | ヒトエリスロフェロン抗体及びその使用 |
| WO2018182529A1 (en) * | 2017-03-29 | 2018-10-04 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| JP7388798B2 (ja) | 2017-06-20 | 2023-11-29 | アンスティテュート キュリー | Ｓｕｖ３９ｈ１を欠損する免疫細胞 |
| KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| MA50855A (fr) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Procédé de génération de compositions thérapeutiques de cellules modifiées |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| MA50859A (fr) | 2017-11-01 | 2020-09-09 | Celgene Corp | Procédé pour la production d'une composition de lymphocytes t |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| EP3720480A2 (en) | 2017-12-08 | 2020-10-14 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| CA3084445A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| EA202092088A1 (ru) | 2018-03-05 | 2020-11-13 | Янссен Фармацевтика Нв | Антитела анти-phf-тау и их применение |
| WO2020002579A1 (en) | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
| BR112021002245A2 (pt) | 2018-08-09 | 2021-05-04 | Juno Therapeutics Inc | métodos para avaliar ácidos nucleicos integrados |
| CN109406798A (zh) * | 2018-10-29 | 2019-03-01 | 美康生物科技股份有限公司 | 肌酐酶法检测试剂盒 |
| MX2021005022A (es) | 2018-11-01 | 2021-09-08 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d). |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| IL263394A (en) * | 2018-11-29 | 2020-05-31 | Amit Ido | Methods of activating dysfunctional immune cells and treatment of cancer |
| MX2021013223A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos. |
| AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| WO2021092044A1 (en) | 2019-11-05 | 2021-05-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
| MX2022009584A (es) * | 2020-02-05 | 2022-10-07 | Navaux Inc | Anticuerpos anti-hepsina y usos de los mismos. |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| WO2021231657A1 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| CN116096864A (zh) | 2020-07-30 | 2023-05-09 | 居里研究所 | Socs1缺陷的免疫细胞 |
| US12540195B2 (en) * | 2020-08-06 | 2026-02-03 | Promab Biotechnologies, Inc. | CS1-antibody and anti-CS1-CAR-T cells |
| WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
| US20240269282A1 (en) | 2021-05-10 | 2024-08-15 | Institut Curie | Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases |
| US20250304915A1 (en) | 2021-05-25 | 2025-10-02 | Institut Curie | Myeloid Cells Overexpressing BCL2 |
| EP4456910A1 (en) | 2021-12-28 | 2024-11-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
| WO2023187024A1 (en) | 2022-03-31 | 2023-10-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| CN115141825A (zh) * | 2022-08-12 | 2022-10-04 | 武汉希望组生物科技有限公司 | 一种微小型昆虫基因组dna的提取方法 |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| WO2024114691A1 (en) * | 2022-12-02 | 2024-06-06 | Guangzhou Litai Biotechnology Co., Ltd. | Human cs1 car-t cells |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| CN121002052A (zh) | 2023-02-03 | 2025-11-21 | C3S2 有限公司 | 用于非病毒生产工程化免疫细胞的方法 |
| US20260001951A1 (en) | 2024-06-28 | 2026-01-01 | Immunitybio, Inc. | Anti-SLAMF7 Antibodies And Therapeutics |
| WO2026093520A1 (en) | 2024-10-31 | 2026-05-07 | Institut Curie | Short-csf1-associated extracellular vesicles and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5004692A (en) | 1987-12-15 | 1991-04-02 | Protein Design Labs, Inc. | Cloning and expression of phosopholipase C genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| US20020099179A1 (en) * | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| JPH07101999A (ja) * | 1993-10-06 | 1995-04-18 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列 |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| AU6094696A (en) | 1995-06-05 | 1996-12-24 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
| US6607898B1 (en) * | 1996-03-26 | 2003-08-19 | Oncomedx, Inc. | Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum |
| WO1999063088A2 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Membrane-bound proteins and nucleic acids encoding the same |
| CA2284550A1 (en) * | 1997-03-21 | 1998-10-01 | Human Genome Sciences, Inc. | 87 human secreted proteins |
| AU6020599A (en) | 1998-08-25 | 2000-03-14 | Incyte Pharmaceuticals, Inc. | Cell surface immunomodulators |
| US20030190669A1 (en) * | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2361293A1 (en) | 1999-02-10 | 2000-08-17 | Human Genome Sciences, Inc. | 33 human secreted proteins |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU3750000A (en) | 1999-03-15 | 2000-10-04 | Eos Biotechnology, Inc. | Reusable low fluorescent plastic biochip |
| AU3774300A (en) | 1999-06-02 | 2000-12-18 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2380355A1 (en) | 1999-09-01 | 2001-03-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2911601A (en) * | 1999-12-23 | 2001-07-03 | Bristol-Myers Squibb Company | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2001071005A2 (en) * | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| WO2001091793A1 (en) | 2000-05-26 | 2001-12-06 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| KR20030091978A (ko) * | 2001-01-29 | 2003-12-03 | 아이덱 파마슈티칼즈 코포레이션 | 변형된 항체 및 사용 방법 |
| EP1379132A4 (en) | 2001-03-21 | 2009-07-01 | Human Genome Sciences | SEPARATE HUMAN PROTEINS |
| US20030099974A1 (en) * | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| WO2003018621A2 (en) | 2001-08-23 | 2003-03-06 | Oxford Biomedica (Uk) Limited | Genes |
| US20040038877A1 (en) | 2001-10-02 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US6478825B1 (en) * | 2001-11-28 | 2002-11-12 | Osteotech, Inc. | Implant, method of making same and use of the implant for the treatment of bone defects |
| US7041499B2 (en) * | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| WO2010051391A1 (en) | 2008-10-31 | 2010-05-06 | Facet Biotech Corporation | Use of anti-cs1 antibodies for treatment of rare lymphomas |
| WO2013037693A2 (de) | 2011-09-15 | 2013-03-21 | Convergent Information Technologies Gmbh | System und verfahren zur automatisierten erstellung von roboterprogrammen |
| CA2866478C (en) | 2012-02-13 | 2019-07-23 | Radius Engineering Inc. | Reusable cartridge for injection molding |
-
2004
- 2004-05-07 US US10/842,011 patent/US20050025763A1/en not_active Abandoned
- 2004-05-10 EP EP04760993A patent/EP1624892B1/en not_active Expired - Lifetime
- 2004-05-10 DK DK14178061.9T patent/DK2853272T3/da active
- 2004-05-10 SI SI200432193T patent/SI2371391T1/sl unknown
- 2004-05-10 PL PL14178061T patent/PL2853272T3/pl unknown
- 2004-05-10 ES ES10183377.0T patent/ES2516840T3/es not_active Expired - Lifetime
- 2004-05-10 HU HUE14178061A patent/HUE034908T2/hu unknown
- 2004-05-10 AU AU2004238363A patent/AU2004238363B2/en not_active Expired
- 2004-05-10 MX MXPA05012011A patent/MXPA05012011A/es active IP Right Grant
- 2004-05-10 DK DK10183377.0T patent/DK2371391T3/da active
- 2004-05-10 SI SI200432408T patent/SI2853272T1/sl unknown
- 2004-05-10 PT PT101833770T patent/PT2371391E/pt unknown
- 2004-05-10 PT PT141780619T patent/PT2853272T/pt unknown
- 2004-05-10 PL PL04760993T patent/PL1624892T3/pl unknown
- 2004-05-10 EP EP10183377.0A patent/EP2371391B1/en not_active Expired - Lifetime
- 2004-05-10 EP EP17176948.2A patent/EP3275463A1/en not_active Withdrawn
- 2004-05-10 EP EP14178061.9A patent/EP2853272B1/en not_active Expired - Lifetime
- 2004-05-10 AT AT04760993T patent/ATE506076T1/de active
- 2004-05-10 DE DE602004032328T patent/DE602004032328D1/de not_active Expired - Lifetime
- 2004-05-10 CA CA2523001A patent/CA2523001C/en not_active Expired - Lifetime
- 2004-05-10 DK DK04760993.8T patent/DK1624892T3/da active
- 2004-05-10 SI SI200431707T patent/SI1624892T1/sl unknown
- 2004-05-10 WO PCT/US2004/014866 patent/WO2004100898A2/en not_active Ceased
- 2004-05-10 PT PT04760993T patent/PT1624892E/pt unknown
- 2004-05-10 CN CN2004800164542A patent/CN1805755B/zh not_active Expired - Lifetime
- 2004-05-10 PL PL10183377T patent/PL2371391T3/pl unknown
- 2004-05-10 ES ES14178061.9T patent/ES2643289T3/es not_active Expired - Lifetime
- 2004-05-10 BR BRPI0410129A patent/BRPI0410129B8/pt not_active IP Right Cessation
- 2004-05-10 LT LTEP14178061.9T patent/LT2853272T/lt unknown
- 2004-05-10 JP JP2006532992A patent/JP4887152B2/ja not_active Expired - Lifetime
-
2005
- 2005-11-07 KR KR1020057021141A patent/KR101268707B1/ko not_active Expired - Lifetime
-
2009
- 2009-03-10 US US12/401,531 patent/US20090238827A1/en not_active Abandoned
- 2009-03-10 US US12/401,513 patent/US8133981B2/en not_active Expired - Lifetime
- 2009-11-02 US US12/610,899 patent/US8008450B2/en not_active Expired - Lifetime
-
2010
- 2010-08-25 AU AU2010214661A patent/AU2010214661B2/en not_active Expired
-
2011
- 2011-06-30 US US13/174,134 patent/US8445646B2/en not_active Expired - Fee Related
- 2011-07-14 CY CY20111100687T patent/CY1111958T1/el unknown
- 2011-09-22 JP JP2011207654A patent/JP5976288B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-15 US US13/894,857 patent/US9175081B2/en not_active Expired - Lifetime
-
2014
- 2014-02-20 JP JP2014030549A patent/JP6042834B2/ja not_active Expired - Lifetime
- 2014-10-23 CY CY20141100872T patent/CY1115671T1/el unknown
-
2015
- 2015-09-22 US US14/860,906 patent/US10442859B2/en not_active Expired - Lifetime
- 2015-09-29 HK HK15109572.0A patent/HK1208815A1/en unknown
-
2016
- 2016-07-20 JP JP2016142300A patent/JP2017019795A/ja active Pending
- 2016-10-20 HU HUS1600042C patent/HUS1600042I1/hu unknown
- 2016-10-24 LU LU93274C patent/LU93274I2/fr unknown
- 2016-10-24 BE BE2016C056C patent/BE2016C056I2/fr unknown
- 2016-10-25 NL NL300838C patent/NL300838I2/nl unknown
- 2016-10-26 CY CY2016035C patent/CY2016035I1/el unknown
- 2016-10-27 FR FR16C1012C patent/FR16C1012I2/fr active Active
-
2017
- 2017-09-15 CY CY20171100980T patent/CY1119353T1/el unknown
-
2019
- 2019-10-10 US US16/599,035 patent/US20200031929A1/en not_active Abandoned